Hildegard Schuller

Prof. Hildegard Schuller

Experimental Oncology Laboratory, Department of Biomedical and Diagnostic Sciences, College of Veterinary Medicine, University of Tennessee, 2407 River Drive, Knoxville, TN 37996, USA

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 February 2009 in Nature Reviews Cancer
Verified
Journal Article
Closed access
HSHildegard Schuller
Hildegard Schuller

1 June 2002 in Nature Reviews Cancer
Verified
Journal Article
Closed access
PDF file
HSHildegard Schuller
Hildegard Schuller

28 February 2008 in Carcinogenesis
Verified
Journal Article
Open access
PDF file
HSHildegard Schuller
Hildegard Schuller
HAHussein A.N. Al-Wadei
Hussein A.N. Al-Wadei
MMMourad Majidi
Mourad Majidi
Pulmonary adenocarcinoma (PAC) is the leading type of lung cancer in smokers and non-smokers that arises in most cases from small airway epithelial cells. PAC has a high mortality due to its aggressive behavior and resistance to cancer therapeutics. We have shown previously that the proliferation of human PAC cells NCI-H322 and immortalized human small airway epithelial cells HPL1D is stimulated by cyclic adenosine monophosphate (cAMP)/protein kinase A-dependent phosphorylation of cyclic adenosine monophosphate response element-binding (CREB) protein and transactivation of the epidermal growth factor receptor and that this pathway is activated by beta-1-adrenoreceptors (β 1 -ARs) and the non-genomic estrogen receptor beta. Our current in vitro studies with HPL1D and NCI-H322 cells showed that signaling via the gamma-amino butyric acid receptor (GABA B R) strongly inhibited base level and isoproterenol-induced cAMP, p-CREB, cyclic adenosine monophosphate response element-luciferase activity and p-extracellular regulated kinase-1 (ERK1)/2 and effectively blocked DNA synthesis and cell migration. The inhibitory effects of gamma-amino butyric acid (GABA) were disinhibited by the GABA B R antagonist CGP-35348 or GABA B R knockdown. Immunohistochemical investigation of hamster lungs showed significant underexpression of GABA in animals with small airway-derived PACs induced by the nicotine-derived carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK). These findings suggest that GABA may have tumor suppressor function in small airway epithelia and the PACs derived from them and that downregulation of GABA by NNK may contribute to the development of this cancer in smokers. Our findings suggest that marker-guided treatment with GABA or a GABA B R agonist of individuals with downregulated pulmonary GABA may provide a novel targeted approach for the prevention of PAC in smokers.

1 July 2009 in Anti-Cancer Drugs
Verified
Journal Article
Closed access
HAHussein A. Al-Wadei
Hussein A. Al-Wadei
MAMohammed H. Al-Wadei
Mohammed H. Al-Wadei
HSHildegard Schuller
Hildegard Schuller
Pancreatic ductal adenocarcinoma (PDAC) is among the leading causes of cancer deaths and is unresponsive to existing therapy. Smoking and alcohol-induced pancreatitis are among the risk factors for PDAC. We have previously reported that beta-adrenergic receptors (β-ARs) stimulate the proliferation and migration of human PDAC cells in vitro by cAMP-dependent signaling and that the nicotine-derived nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) activates this pathway directly in vitro while additionally stimulating the release of noradrenaline/adrenaline by binding to α7 nicotinic acetylcholine receptors (α7 nAChR) in hamsters. In this study, we have tested the hypothesis that the β-AR antagonist propranolol prevents the development of PDAC induced in hamsters with ethanol-induced pancreatitis by NNK. We found that propranolol had strong cancer preventive effects in this animal model. Western blots of pancreatic duct cells and PDAC cells harvested by laser capture microscopy showed significant upregulation of the α7 nAChR associated with significant inductions of p-CREB, p-ERK1/2, and increases in epidermal growth factor and vascular endothelial growth factor in PDAC cells of hamsters not treated with propranolol. These effects were reversed by treatment with propranolol. Our data suggest that propranolol may prevent the development of PDAC by blocking cAMP-dependent intracellular signaling, cAMP-dependent release of epidermal growth factor, and PKA-dependent release of vascular endothelial growth factor while additionally downregulating the α7 nAChR by inhibiting cAMP-mediated subunit assembly. We conclude that increased cAMP signaling is an important factor that drives the development and progression of PDAC and that the inhibition of cAMP formation is a promising new target for the prevention and adjuvant therapy of PDAC.

1 May 2007 in Life Sciences
Verified
Journal Article
Closed access
HSHildegard Schuller
Hildegard Schuller

1 February 2008 in Cancer
Verified
Journal Article
Open access
PDF file
HSHildegard Schuller
Hildegard Schuller
HAHussein A. N. Al‐Wadei
Hussein A. N. Al‐Wadei
MMMourad Majidi
Mourad Majidi
BACKGROUND.: Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer death. Smoking, diabetes, and pancreatitis are risk factors. It has been shown that the growth of PDAC and pancreatic duct epithelial cells is regulated by beta‐adrenoreceptors (β‐ARs). The activity of β‐ARs in the central nervous system is counteracted by γ‐aminobutyric acid (GABA) via GABAB receptor‐mediated inhibition of adenylyl cyclase. The aim of the study was to investigate if GABABR inhibits β‐AR signaling in PDAC and pancreatic duct epithelial cells, thus blocking driving forces of cancer progression, such as cell proliferation and cell migration.METHODS.: Intracellular cAMP was measured by immunoassays, DNA synthesis by BrdU incorporation assays, activation of ERK1/2 by ERK activation assays, and Western blots and metastatic potential by cell migration assays in the human PDAC cell lines PANC‐1 and BXPC‐3 and immortalized human pancreatic duct epithelial cells HPDE6‐C7. The expression of norepinephrine, PKARIIα, and GABA in PDAC microarrays was assessed by immunohistochemistry.RESULTS.: Stimulation of the GABABR by GABA or baclofen inhibited isoproterenol‐induced cAMP signaling below base levels. ERK1/2 activity in response to isoproterenol was blocked by GABA, an effect enhanced by transient overexpression of the GABABR and abolished by GABABR knockdown. DNA synthesis and cell migration were stimulated by isoproterenol, responses blocked by GABA and baclofen. Norepinephrine and PKARIIα were overexpressed while GABA was underexpressed in human PDAC tissue arrays.CONCLUSIONS.: The data suggest the stimulation of GABABR signaling as a novel target for the treatment and prevention of pancreatic cancer. Cancer 2008. © 2007 American Cancer Society.